Effects of edoxaban, rivaroxaban, and warfarin on recanalisation, inflammation, and post-thrombotic syndrome in patients with deep vein thrombosis.

Objective: Post-thrombotic syndrome (PTS) and recurrent thrombosis are the common morbidities associated with deep venous thrombosis (DVT). There are several treatment modalities have been defined in the literature. Here, we aimed to compare the effects of edoxaban, rivaroxaban and warfarin on recanalised flow, inflammation and postthrombotic syndrome in patients with DVT.

Methods: A total of 320 patients treated with Edoxaban 60 mg(n = 107), Rivaroxaban 20 mg(n = 107) and Warfarin 5 mg(n = 106) due to DVT were included to the study. Venous Doppler ultrasonography and VILLALTA score were used for the assessment of recanalised flow and PTS.

Results: There were no statistically significant differences between the groups in terms of demographic characteristics. 1-month NLR levels were significantly lower in rivaroxaban group and PLR levels were significantly lower in both rivaroxaban and edoxaban groups. 3-month villalta score was statistically higher inWarfarin group and no differences in 6^th month measurements between the groups.

Conclusions: Treatment of DVT is a dynamic process which requires the exact evaluation of the patients according to the several parameters. Recanalised flow, inflammation and situations related to inflammation such as PTS can be used for the assessment. Drugs can be shifted according to the response.

Abbreviations and acronyms: DVT: Deep Venous Thrombosis, PTS: Post-thrombotic Syndrome, NOACs: New Oral Anticoagulants, NLR: Neutrophil/lymphocyte ratio, PLR: Platelet/lymphocyte ratio, TTR: Time in therapeutic range, QoL: Quality of Life.